Yamada Tadataka 4
4 · Prometheus Biosciences, Inc. · Filed Mar 16, 2021
Insider Transaction Report
Form 4
Yamada Tadataka
DirectorOther
Transactions
- Conversion
Common Stock
[F1]2021-03-16+13,333→ 13,333 total - Conversion
Series B Preferred Stock
[F1]2021-03-16−133,334→ 0 total→ Common Stock (13,333 underlying)
Footnotes (1)
- [F1]The shares of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering.
Signature
/s/ Timothy K. Andrews, as attorney-in-fact for Tadataka Yamada|2021-03-16